trial

Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia

NCTId NCT02234752
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2 · Terminated
Enrollment 3 (actual)
Sponsored by Sheppard Pratt Health System
Primary completion 2016-07
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2
Status
Terminated
Enrollment
3 (actual)
Study type
Interventional
Allocation
Na
Model
Single Group
Masking
None
Start
2014-09
Primary completion
2016-07
Eligibility
ALL · 18 Years · 55 Years

Interventions & indications

Drugs
Galantamine ERMemantine XR

Sponsors

Sheppard Pratt Health SystemLead Sponsor

Investigators

1
Maju M. Koola, MDPrincipal Investigator

Sites

1 total
Baltimore, United States

Linked catalysts

1
Galantamine and Memantine Combination for Cognitive Impairments in Schizophrenia — primary completion2016-07

Facts & assertions

4 sourced
Enrollment
3
Phase
PHASE2
Primary Completion Date
2016-07
Status
TERMINATED
relationships
The graph out of here
drug
Galantamine ER
drug
Memantine XR
drug
lead_sponsor
Sheppard Pratt Health System
company
indication
Schizoaffective Disorder
indication
Cognitive Dysfunction
indication
Schizophrenia
indication
investigator
Maju M. Koola, MD
person